The fight for dominance between Regeneron and Bayer’s big blockbuster eye drug Eylea and Roche’s rival Vabysmo is playing out ...

The drug could become the first approved treatment option for women who suffer from hot flashes as they undergo adjuvant endocrine therapy - a treatment for breast cancer. Bayer is facing several ...

Growth is on the horizon for German drug conglomerate Bayer (BAYRY), despite “falling sales of its blockbuster blood thinner Xarelto,”amid generic competition, wrote Connor Hart for the Wall ...

The global aspirin drug market is poised for substantial growth over the next decade, with its value expected to increase ...

Bayer now says it expects to make €3 billion in sales for its prostate cancer treatment Nubeqa, up from an earlier estimate of €1 billion, after reviewing new data for the drug in metastatic ...

Anthos Therapeutics' abelacimab shows lower bleeding risk vs Xarelto in atrial fibrillation trial, with 62% reduction in ...

Additionally, the ophthalmology drug Eylea™ saw an 8.6% increase in sales. However, these positive developments were offset by a 23% decline in sales of Xarelto, which is Bayer's blockbuster ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Bayer expects its pharmaceutical business to ... for symptoms of menopause — later this year. It hopes these new drugs will offset falling sales of its blockbuster blood thinner Xarelto, which ...

Berenberg Bank analyst Sebastian Bray maintained a Hold rating on Bayer (0P6S – Research Report) today and set a price target of €22.00. The ...